BNT162b5: Clinical Trials

2 trials of BNT162b5, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 withdrawn. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Active not recruiting 1, Withdrawn 1

Follow BNT162b5: new trials by email Literature Review of BNT162b5 trials Research Report on BNT162b5

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial
Pfizer Bivalent COVID-19 Vaccine, Moderna Bivalent mRNA vaccine - HIV, Organ Transplantation
Phase 3Active not recruitingMonash University9602022-12-012025-10-03
COVID-19 Fourth Dose Study in Australia
Tozinameran, Elasomeran, Bivalent Pfizer-BioNTech - COVID-19
Phase 3WithdrawnMurdoch Childrens Research Institute2022-05-022024-03-15

Conditions studied

COVID-19 (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)

Sponsors

Monash University (1)  ·  Murdoch Childrens Research Institute (1)

Countries

Australia (2)

Top investigators

James H McMahon, MBBS PhD (1)  ·  Kim Mulholland, MD/Prof (1)

Results publications

PMID 39020446, PMID 39978439, PMID 40396505, PMID 40713834